

In re Application of:

Evans et al.

Application No.: 08/931,694

Filed: September 16, 1997

Page 2

PATENT

Attorney Docket No.: SALK1280-4


In The Claims

B3  
Please cancel claims 2-4 and 9-15 without prejudice and amend claim 1 as follows:

B1  
1. (Amended) A method for the treatment of ~~[a subject afflicted with]~~ a steroid or steroid-like hormone-responsive disease state in a subject in need thereof, said method comprising administering to said subject an effective amount of a ligand which selectively interacts with the receptor subtype associated with said steroid or steroid-like hormone responsive disease state, to a significantly greater extent than with other subtypes of the same receptor class.

Please add new claims 16-18 as follows:

16. (New) A method according to Claim 5 wherein said RAR- $\alpha$  selective ligand is the amide:



In re Application of:

Evans et al.

Application No.: 08/931,694


Filed: September 16, 1997

Page 3


PATENT

Attorney Docket No.: SALK1280-4

17. (New) A method according to Claim 5 wherein said RAR- $\beta$  selective ligand is the phenyl-naphthyl derivative:



or benzophenone derivative:



18. (New) A method according to Claim 5 wherein said RAR- $\gamma$  selective ligand is the phenyl-naphthyl derivative:

